[Multiple drug resistance: a threat for tuberculosis control]. / La resistencia a múltiples fármacos: una amenaza para el control de la tuberculosis.

Drug-resistant tuberculosis (TB) was reported soon after the introduction of streptomycin, although it did not receive major attention until recently. It was not considered a major issue in the industrialized world until outbreaks of multidrug-resistant TB (MDR-TB) were reported among HIV infected people. Administration of standard short-course chemotherapy (SSCC) with first-line drugs under directly observed therapy (DOT) is the cornerstone of modern TB control. Unfortunately, data available on the treatment outcome of MDR-TB cases under routine programmatic conditions suggest that patients with MDR-TB respond poorly to SSCC with first-line drugs. Since 1994, the World Health Organization and the International Union Against Tuberculosis and Lung Disease (IU-ATLD) have conducted anti-TB drug resistance surveys through a network of subregional laboratories and researchers. Drug resistance was present in almost all settings surveyed, and prevalence varied widely across regions. High prevalence of MDR-TB is widespread in the Russian Federation and areas of the former Soviet Union (Estonia, Kazakhstan, Latvia, and Lithuania) as well as Israel, Liaoning and Henan Provinces in China, and Ecuador. The Global Project has surveyed areas representing over one third of notified TB cases. However, enormous gaps still exist in the most crucial areas. The most effective strategy to prevent the emergence of drug resistance is through implementation of the directly observed treatment short (DOTS) strategy. Effective implementation of the DOTS strategy saves lives through decreased TB transmission, decreased risk of emergence of drug-resistance, and decreased risk for individual TB patients of treatment failure, TB relapse, and death. The World Bank recognizes the DOTS strategy as one of the most cost-effective health interventions, and recommends that effective TB treatment be a part of the essential clinical services package available in primary health care settings. Governments are responsible for ensuring the provision of effective TB control through the DOTS strategy. WHO and its international partners have formed the DOTS-Plus Working Group, which is attempting to determine the best possible strategy to manage MDR-TB. One of the goals of DOTS-Plus is to increase access to expensive second-line anti-TB drugs for WHO-approved TB control programmes in low- and middle-income countries.

La resistencia a múltiples fármacos: una amenaza para el control de la tuberculosis / Multiple drug resistance: a threat for tuberculosis control

Drug-resistant tuberculosis (TB) was reported soon after the introduction of streptomycin, although it did not receive major attention until recently. It was not considered a major issue in the industrialized world until outbreaks of multidrug-resistant TB (MDR-TB) were reported among HIV infected people. Administration of standard short-course chemotherapy (SSCC) with first-line drugs under directly observed therapy (DOT) is the cornerstone of modern TB control. Unfortunately, data available on the treatment outcome of MDR-TB cases under routine programmatic conditions suggest that patients with MDR-TB respond poorly to SSCC with first-line drugs. Since 1994, the World Health Organization and the International Union Against Tuberculosis and Lung Disease (IUATLD) have conducted anti-TB drug resistance surveys through a network of subregional laboratories and researchers. Drug resistance was present in almost all settings surveyed, and prevalence varied widely across regions. High prevalence of MDR-TB is widespread in the Russian Federation and areas of the former Soviet Union (Estonia, Kazakhstan, Latvia, and Lithuania) as well as Israel, Liaoning and Henan Provinces in China, and Ecuador. The Global Project has surveyed areas representing over one third of notified TB cases. However, enormous gaps still exist in the most crucial areas. The most effective strategy to prevent the emergence of drug resistance is through implementation of the directly observed treatment short (DOTS) strategy. Effective implementation of the DOTS strategy saves lives through decreased TB transmission, decreased risk of emergence of drug- resistance, and decreased risk for individual TB patients of treatment failure, TB relapse, and death. The World Bank recognizes the DOTS strategy as one of the most cost-effective health interventions, and recommends that effective TB treatment be a part of the essential clinical services package available in primary health care settings. Governments are responsible for ensuring the provision of effective TB control through the DOTS strategy. WHO and its international partners have formed the DOTS-Plus Working Group, which is attempting to determine the best possible strategy to manage MDR-TB. One of the goals of DOTS-Plus is to increase access to expensive second-line anti-TB drugs for WHO-approved TB control programmes in low- and middle-income countries.

[Disseminated mycobacteriosis associated with Mycobacterium avium-intracellular (MAI) complex in HIV infected patients]. / Micobacteriosis diseminada asociada al complejo Mycobacterium avium-intracellulare (MAI), en paciente infectado con el virus de inmunodeficiencia humana.

Different types of samples from a 27-year-old female patient who was diagnosed AIDS after presenting an acute respiratory picture caused by Pneumocistis carinii, in 1997, were studied. From that moment on, the patient continued having respiratory pictures repeatedly, until she was admitted at "Pedro Kouri" Institute of Tropical Medicine with a chronic diarrheical picture, significant loss of weight and extreme anorexia, together with a constant wet cough, fever, etc. The necessary complementary tests were made and a hyperergic Mantoux and very low levels of CD4 cells (under 200 cells/m3) outstood. Microbiological studies were also conducted with samples from sputum, hemocultures and cerebrospinal fluid to discard the presence of acid-alcohol resistant bacilli (AARB). As a result of these studies, the repeated isolation was obtained in all types of worked samples from a slow-growth, creamy and non pigmented strain corresponding to Runyon's group III, which was classified as from the Mycobacterium avium-intracellulare complex. The patient was treated with antibacillary drugs without results, since she dies 4 weeks later due to the total dissemination of this infection. It should be stressed that it is the first case reported and microbiologically diagnosed of a generalized mycobacteriosis in a HIV positive patient due to Mycobacterium avium-intracellulare.

Evaluación de la prueba de la pirazinamidasa para la determinación de la susceptibilidad de Mycobacterium tuberculosis a la pirazinamida / Evaluation of the pyrazinamidase test for the detection of susceptibility of Mycobacterium tuberculosis to pyrazinamide

The pyrazinamidase test was used to determine susceptibility to pyrazinamide in 55 strains of Mycobacterium tuberculosis received at the National Laboratory of Reference and Research of Tuberculosis and Mycobacteria of the "Pedro KourÝ" Institute of Tropical Medicine during the first semester of 1997. On comparing the results obtained with the method of proportions, it was attained a correlation of 83.6 of sensitivity with 16.4 of false positives. It was proved that the pyrazinamidase test should not replace the method of proportions.